Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NVP-1805-R1 + NVP-1805-R2 is an investigational oral combination of two small molecule drugs developed by Navipharm and evaluated by NVP Healthcare. The combination has been studied in Phase 1 clinical trials to assess pharmacokinetic interactions, safety, and tolerability when coadministered in healthy adult volunteers. Both components—NVP-1805-R1 and NVP-1805-R2—are also being investigated individually. The primary therapeutic area under investigation is cardiovascular diseases, with additional interest in vascular diseases. No detailed mechanism of action or molecular targets have been disclosed publicly for either component[1][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NVP-1805-R1 + NVP-1805-R2.